Anoxic insult Stroke/Cerebrovascular accident

Similar documents
Form 4: Coronary Evaluation

Form 4: Coronary Evaluation

4a.i. 4a.ii. Form 12: Pre Transplant Status Report. Height and Weight. Status.

Donor Height Centimeters Inches Missing Reason: Not Done Unknown. Donor Weight Kilograms Pounds Missing Reason: Not Done Unknown. Female Male Unknown

Solid Organ Transplant

Supplementary material 1. Definitions of study endpoints (extracted from the Endpoint Validation Committee Charter) 1.

Transplant in Pediatric Heart Failure

Form 8: Post Transplant Annual Followup

5a.i. Center Code. Patient Initials. Is patient under the age of 18 at the time of listing? Was informed consent and HIPAA Authorization obtained?

4 Has this patient been transplanted No

Transplantation in Australia and New Zealand

Form 8: Post Transplant Annual Followup

a. Ischemic stroke An acute focal infarction of the brain or retina (and does not include anterior ischemic optic neuropathy (AION)).

Screening Log. Center Code DCC. Patient Initials. Is patient under the age of 18 at the time of listing?

Supplement Table 1. Definitions for Causes of Death

3/6/2017. Treatment of Detected Antibodies. I have financial relationship(s) with: Thoratec/St. Jude/Abbott Consultant CareDx Consultant/Speaker

4. Which survey program does your facility use to get your program designated by the state?

Pulmonary AMR Therapeutic Options & Strategies: The Old and the New. Ramsey Hachem, MD March 28, 2017

Months Years. Centimeters Inches Missing Reason: Not Done Unknown. Kilograms Pounds Missing Reason: Not Done Unknown. Female Male Unknown

Form 4: Coronary Evaluation

STEPHEN P. NONN OFFICE OF THE CORONER MADISON COUNTY, ILLINOIS 157 MAIN STREET SUITE 354 EDWARDSVILLE, IL

APHERESIS FOR DESENSITIZATION OF NON-RENAL TRANSPLANTS

Causes of Death. J. Douglas Rizzo, MD MS February, New11_1.ppt

HSCT - Minimum Essential Data - A FOLLOW UP REPORT - ANNUAL

Ontario s Referral and Listing Criteria for Adult Heart Transplantation

This appendix was part of the submitted manuscript and has been peer. Pre-existing cardiovascular disease was defined by the presence of any of the

* PLACE OF SERVICE REQUIREMENTS FOR ADDITIONAL HIGHMARK WV MEDICAL POLICIES ANNOUNCED IN THE FEBRUARY 2011 ISSUE OF PROVIDER NEWS *

AMR in Liver Transplantation: Incidence

Heart Transplant Family Education Class

TYPE II MI. KC ACDIS LOCAL CHAPTER March 8, 2016

ICD-10 Physician Education. Palliative Care SIP

CHAPTER 3 HEART AND LUNG TRANSPLANTATION. Editors: Mr. Mohamed Ezani Hj Md. Taib Dato Dr. David Chew Soon Ping

Predictors of cardiac allograft vasculopathy in pediatric heart transplant recipients

No evidence of C4d association with AMR However, C3d and AMR correlated well

2/28/2017. Adult Heart Transplants Donor and Recipient Characteristics UNOS, Retransplant VCM. Other /2015 (N = 24,474)

Myocardial Infarction In Dr.Yahya Kiwan

Understanding Myositis Medications

ECLS Registry Form Extracorporeal Life Support Organization (ELSO)

Chapter 9: Cardiovascular Disease in Patients With ESRD

Yes No Unknown. Major Infection Information

Indications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014

Imminent Cardiac Collapse: The Catastrophe You Cannot Afford To Miss

IMMUNOBIOLOGY OF TRANSPLANTATION. Wasim Dar

InterQual Level of Care 2018 Index

Data Fact Sheet. Congestive Heart Failure in the United States: A New Epidemic

Heart Transplantation for Patients with a Fontan Procedure

ACUTE KIDNEY INJURY (AKI) ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) ADVANCED DIRECTIVE LIMITING CARE...91 AGE...9 AGE UNITS...

Disclosures (2013 to the present)

Advanced Heart Failure and Transplant Cardiology

Adverse Event. Adverse Event Status. Please enter the date of the event you are reporting: Please enter a label describing this event:

Outcomes From Severe ARDS Managed Without ECMO. Roy Brower, MD Johns Hopkins University Critical Care Canada Forum Toronto November 1, 2016

Figure 1. Actuarial survival of patients with ABO I, ABO compatible, and ABO identical grafts.

Preoperative tests (update)

Supplemental Appendix. 1. Protocol Definition of Sustained Virologic Response. A patient has a sustained virologic response if:

Heart Transplantation ACC Middle East Conference Dubai UAE October 21, 2017

Heart Transplantation is Dead

COMPLETING THE MEDICAL CERTIFICATE OF DEATH

Olive J Sturtevant, MHP, MT(ASCP)SBB/SLS, CQA Director, Cellular Therapy Quality Assurance Dana Farber Cancer Institute

Transfusion Reactions. Directed by M-azad March 2012

Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 (MOMENTUM 3) Long Term Outcomes

Desensitization in Kidney Transplant. James Cooper, MD Assistant Professor, Kidney and Pancreas Transplant Program, Renal Division, UC Denver

To ECMO Or Not To ECMO Challenges of venous arterial ECMO. Dr Emily Granger St Vincent s Hospital Darlinghurst NSW

STEPHEN P. NONN OFFICE OF THE CORONER MADISON COUNTY, ILLINOIS 157 MAIN STREET SUITE 354 EDWARDSVILLE, IL

Acute Coronary Syndrome

Q1 Contact Information

Protecting the heart and kidney: implications from the SHARP trial

Appendix to Notification Letter for rituximab and eltrombopag dated 20 February 2014

Appendix 1: Supplementary tables [posted as supplied by author]

Cardiac surgery - CAD

New perspec)ves on withdrawal from dialysis. Jennifer Chan, Phil Clayton, Stephen McDonald, John Agar, Ma?hew Jose

Antibody Mediated Rejection (AMR) in LUNG TRANSPLANT Recipients

Policy Specific Section: May 16, 1984 April 9, 2014

DEMYSTIFYING VADs. Nicolle Choquette RN MN Athabasca University

Pulmonary Embolectomy:

2016 Physician Quality Reporting System Data Collection Form: Coronary Artery Bypass Graft (CABG) (for patients aged 18 years and older)

Veno-Venous ECMO Support. Chris Cropsey, MD Sept. 21, 2015

Form 4: Coronary Evaluation

Hong Ryang Kil, MD, PhD Department of Pediatrics, School of Medicine Chungnam National University, Daejeon, Korea

TROPONIN POSITIVE 2/20/2015 WHAT DOES IT MEAN? When should a troponin level be obtained?

ABO mismatched Renal Transplants

Cancer and Heart/Stroke

ICU Referral For Common Medical Disorders. Prof. M A Jalil Chowdhury

Desensitization protocols for patients undergoing solid organ transplantation

UCLA General Surgery Residency Program Rotation Educational Policy Goals and Objectives ROTATION: SURGICAL CRITICAL CARE AND TRANSPLANTATION SURGERY

Arkansas Health Care Payment Improvement Initiative Percutaneous Coronary Intervention Algorithm Summary

SYNOPSIS. Clinical Study Report IM Double-blind Period

Myositis and Your Lungs

This study is currently recruiting participants.

Antibody-Mediated Rejection in the Lung Allograft. Gerald J Berry, MD Dept of Pathology Stanford University Stanford, CA 94305

CHAPTER 3 DEATHS. Stephen McDonald Leonie Excell Brian Livingston

Instruct patient and caregivers: Need for constant monitoring Potential complications of drug therapy

Covered Critical Illness Conditions Appendix

Diagnosis and Management of Acute and Chronic Humoral Rejection. Lars Pape

Atrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases?

OPCAB IS NOT BETTER THAN CONVENTIONAL CABG

ARRHYTHMIAS AND DEVICE THERAPY

Acute heart failure: ECMO Cardiology & Vascular Medicine 2012

2011 Dialysis Facility Report

Transplantation: Year in Review

Transcription:

Page 1 of 5 Patient Details Hidden Show Show/Hide Annotations Stickies: Toggle All Toggle Open Toggle Resolved Form 10: Death Print this Form t Started 1 Date of Death MM/DD/YYYY 2 Primary cause of death Cardiac Hepatic Failure Infection Major bleeding Malignancy/Cancer Neurologic Poor donor preservation Primary graft failure (onset <24 hours posttransplant) Pulmonary embolism Pulmonary hypertension/rv failure Rejection Renal Failure Respiratory failure Suicide Trauma/Accidental, *American Heart Association definition of Sudden Cardiac Death (also called sudden arrest) is death resulting from an abrupt loss of heart function (cardiac arrest). The victim may or may not have diagnosed heart disease. The time and mode of death are unexpected. It occurs within minutes after symptoms appear. Do not list support withdrawal as COD. Identify underlying reason i.e.cardiac failure, pulmonary hemorrhage, irreversible brain injury, etc 2d 2a If Neurologic, If Cardiac, Anoxic insult Stroke/Cerebrovascular accident Congestive heart failure Coronary artery disease, (infarction) Fatal arrhythmia Sudden cardiac death, no arrhythmia or MI documented 2c If Malignancy/Cancer, Lymphoma/Lymphoproliferative disease Malignancy, non-lymphoma 2b 2e If Major Bleeding, If Rejection, Post-operative hemorrhage Pulmonary hemorrhage Acute Chronic Hyper acute (onset <24 hours post-transplant)

Page 2 of 5 3 3a Did patient have a contributing cause of death? Cardiac Family decision to withdraw of support Hepatic Failure Infection Major bleeding Malignancy/Cancer Neurologic n-compliance Poor donor preservation Primary graft failure (onset <24 hours posttransplant) Pulmonary embolism Pulmonary hypertension/rv failure Rejection Renal Failure Respiratory failure Suicide Trauma/Accidental, 3a.i If Cardiac, Congestive heart failure Coronary artery disease, (infarction) Fatal arrhythmia Sudden cardiac death, no arrhythmia or MI documented 3a.iii If Malignancy/Cancer, Lymphoma/Lymphoproliferative disease Malignancy, non-lymphoma 3a.ii If Major Bleeding, Post-operative hemorrhage Pulmonary hemorrhage 3a.iv If Neurologic, Anoxic insult Stroke/Cerebrovascular accident

Page 3 of 5 3a.v If Rejection, Hyperacute (onset < 24 hours post transplant) Acute Chronic 4 3a.vi If Trauma/Accidental, Patient supported by IABP/VAD/TAH/ECMO at time of death 5 Was patient listed or relisted at time of death? 5a Status Details Check all that Apply Per UNOS Policy 6.1 On 6/14/2015 Has ductal dependent pulmonary or systemic circulation, with ductal patency maintained by stent of prostaglandin infusion In hospital Out of hospital Requires Inotropes 5a.i ICU Requires continuous 5a.ii mechanical ventilationr 5a.iii On inotropes High dose or multiple IV Single low dose IV Dose 5b 5c 5c.i ABO Incompatible History of PRA > 10% Did the patient receive treatment to lower or manage an

Page 4 of 5 elevated PRA while awaiting transplantation? 5c.i.1 Which therapy was administered? Azathioprine (Imuran) Bortezomib (Velcade) Cytoxan (cyclophosphamide) Immunoglobin (IVIG, IV IgG) Mycophenylate, MMF (Cellcept, Myfortic) Plasmapheresis/plasma exchange Rituximab (Rituxan) 5c.i.2 How long was therapy administered? Only for a pre-specified time/number of treatments: Until Heart transplantation, regardless of subsequent PRA levels/sensitization profile Until PRA level reduced to 0%/patient no longer sensitized Until PRA/sensitization profile diminished to a prespecified goal 6 Post Mortem Examination (autopsy) 6a Cardiac pathology found Check all that apply. Acute Rejection CAD, remote infarction (>1wk) Coronary artery disease, recent infarction (<= 1wk) Diffuse fibrosis, no acute rejection Graftatherosclerosis cardiac pathology found 6a.i ACR Grading 0 1R 2R 3R 2004 revised ISHLT grading system for ACR: (J Heart Lung Transplant. 2005 v;24(11):1710-20.) ACR: acute cellular rejection (0, 1R, 2R, 3R) 6a.ii pamr Grading 0 1h 1i 2 3 t evaluated Positive, score not specified

Page 5 of 5 2013 revised ISHLT grading system for pamr: J Heart Lung Transplant 2013 Dec 32(12):1147-62.) pamr: pathologic antibody mediated rejection (0, 1h, 1i, 2, 3) 7 Were there special circumstances surrounding the death? 7a Comments 2017 PHTS [PHTS]